{"entity":{"type":"insider","cik":"0001311267","url":"/insider/0001311267","json_url":"/insider/0001311267.json","name":"MULYE NIRMAL","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":2,"first":"2006-10-03","last":"2006-10-03","span_basis":"filed_date"},"name_variants":[{"name":"MULYE NIRMAL","source":"filing","n_filings":2,"first_seen":"2006-10-03","last_seen":"2006-10-03"}],"transactions":[{"id":5409316,"accession":"0001144204-06-040673","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-06-040673","line_url":"/filing/0001144204-06-040673#line-1","is_derivative":false,"issuer_cik":"0001030839","issuer_name":"Synovics Pharmaceuticals","issuer_ticker":"SYVC","issuer_name_source":null,"issuer_url":"/issuer/0001030839","owner_cik":null,"owner_name":"Nostrum Pharmaceuticals, Inc.; MULYE NIRMAL","owner_display_name":"Nostrum Pharmaceuticals, Inc.","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":550000.0,"shares_display":"550,000","price_per_share":0.38,"price_display":"0.38","price_state":"stated","total_value":209000.0,"total_display":"209,000.00","total_whole":"209,000","shares_owned_after":10750000.0,"shares_owned_after_display":"10,750,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-01-04","filed_date":"2006-10-03","scope":"insider"},{"id":4010987,"accession":"0001144204-06-040671","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001144204-06-040671","line_url":"/filing/0001144204-06-040671#line-10","is_derivative":false,"issuer_cik":"0001030839","issuer_name":"Synovics Pharmaceuticals","issuer_ticker":"SYVC","issuer_name_source":null,"issuer_url":"/issuer/0001030839","owner_cik":null,"owner_name":"Nostrum Pharmaceuticals, Inc.; MULYE NIRMAL","owner_display_name":"Nostrum Pharmaceuticals, Inc.","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock, par value $0.001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6000000.0,"shares_display":"6,000,000","price_per_share":0.375,"price_display":"0.38","price_state":"stated","total_value":2250000.0,"total_display":"2,250,000.00","total_whole":"2,250,000","shares_owned_after":11300000.0,"shares_owned_after_display":"11,300,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-03-16","filed_date":"2006-10-03","scope":"insider"},{"id":4010986,"accession":"0001144204-06-040671","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001144204-06-040671","line_url":"/filing/0001144204-06-040671#line-9","is_derivative":false,"issuer_cik":"0001030839","issuer_name":"Synovics Pharmaceuticals","issuer_ticker":"SYVC","issuer_name_source":null,"issuer_url":"/issuer/0001030839","owner_cik":null,"owner_name":"Nostrum Pharmaceuticals, Inc.; MULYE NIRMAL","owner_display_name":"Nostrum Pharmaceuticals, Inc.","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":0.4,"price_display":"0.40","price_state":"stated","total_value":8000.0,"total_display":"8,000.00","total_whole":"8,000","shares_owned_after":11300000.0,"shares_owned_after_display":"11,300,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-03-02","filed_date":"2006-10-03","scope":"insider"},{"id":4010982,"accession":"0001144204-06-040671","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001144204-06-040671","line_url":"/filing/0001144204-06-040671#line-7","is_derivative":false,"issuer_cik":"0001030839","issuer_name":"Synovics Pharmaceuticals","issuer_ticker":"SYVC","issuer_name_source":null,"issuer_url":"/issuer/0001030839","owner_cik":null,"owner_name":"Nostrum Pharmaceuticals, Inc.; MULYE NIRMAL","owner_display_name":"Nostrum Pharmaceuticals, Inc.","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":0.4,"price_display":"0.40","price_state":"stated","total_value":2000.0,"total_display":"2,000.00","total_whole":"2,000","shares_owned_after":11300000.0,"shares_owned_after_display":"11,300,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-02-25","filed_date":"2006-10-03","scope":"insider"},{"id":4010980,"accession":"0001144204-06-040671","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001144204-06-040671","line_url":"/filing/0001144204-06-040671#line-6","is_derivative":false,"issuer_cik":"0001030839","issuer_name":"Synovics Pharmaceuticals","issuer_ticker":"SYVC","issuer_name_source":null,"issuer_url":"/issuer/0001030839","owner_cik":null,"owner_name":"Nostrum Pharmaceuticals, Inc.; MULYE NIRMAL","owner_display_name":"Nostrum Pharmaceuticals, Inc.","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":0.4,"price_display":"0.40","price_state":"stated","total_value":8000.0,"total_display":"8,000.00","total_whole":"8,000","shares_owned_after":11300000.0,"shares_owned_after_display":"11,300,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-02-11","filed_date":"2006-10-03","scope":"insider"},{"id":4010978,"accession":"0001144204-06-040671","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001144204-06-040671","line_url":"/filing/0001144204-06-040671","is_derivative":false,"issuer_cik":"0001030839","issuer_name":"Synovics Pharmaceuticals","issuer_ticker":"SYVC","issuer_name_source":null,"issuer_url":"/issuer/0001030839","owner_cik":null,"owner_name":"Nostrum Pharmaceuticals, Inc.; MULYE NIRMAL","owner_display_name":"Nostrum Pharmaceuticals, Inc.","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock, par value $0.001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55000.0,"shares_display":"55,000","price_per_share":0.4,"price_display":"0.40","price_state":"stated","total_value":22000.0,"total_display":"22,000.00","total_whole":"22,000","shares_owned_after":11300000.0,"shares_owned_after_display":"11,300,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-02-01","filed_date":"2006-10-03","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001030839","name":"Synovics Pharmaceuticals","url":"/issuer/0001030839","role":"Director, Officer (Chief Scientific Officer), Ten percent owner","n_filings":2,"first_seen":"2006-10-03","last_seen":"2006-10-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001311267","retrieved_at":"2026-08-27T05:59:52+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}